AzPA Pharmacy Flash

• FDA approves Cobenfy for adults with schizophrenia
  Bristol Myers Squibb's Cobenfy, a first-in-class muscarinic agonist, has been approved for the treatment of schizophrenia in adults, based on the EMERGENT clinical trials. The medication selectively targets M1 and M4 brain receptors without blocking D2 receptors.
• Active feedback improves pharmacist participation in heart failure treatment
  A study presented at the American Heart Association's Scientific Sessions 2024 found that pharmacists who received active feedback about their heart failure patients increased patient interactions and prescribed more medication adjustments.
• PTC wins FDA approval for first brain-delivered gene therapy Kebilidi
  PTC Therapeutics' Kebilidi, the first U.S. gene therapy administered directly in the brain, has received FDA approval to treat the rare AADC deficiency. The minimally invasive procedure boosts the AADC enzyme and restores dopamine production.